Business
Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares
KIRKLAND, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company,
About this update from Kestra Medical Technologies, Ltd.
[{"type":"text","content":"KIRKLAND, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the pricing of its upsized underwritten public offering of 6,000,000 common shares at a price to the public of $23.00 per share. The gross proceeds to Kestra from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $138,000,000. In addition, Kestra has granted the underwriters a 30-day option to purchase up to an additional 900,000 common shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 4, 2025, subject to the satisfaction of customary closing conditions. BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC and Wells Fargo Securities are acting as bookrunners for the offering. The offering is being made only by means of a prospectus. A preliminary prospectus related to the offering has been filed with the SEC and is available on the SEC’s website located at www.sec.gov. A final prospectus related to the offering will be filed with the SEC. Copies of the preliminary prospectus and, when available, the final prospectus, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at [email protected]; Piper Sandler, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at 800-747-3924 or by email at [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at [email protected]. A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (“SEC”) and was declared effective on December 2, 2025. Copies of the registration statement can be accessed by visiting the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall...